peginterferon alfa-2a + entecavir + tenofovir disoproxil fumarate

This therapeutic regimen refers to a sequential combination therapy being evaluated by **Tongji Hospital** in the **COST trial** (NCT03324308) for the treatment of chronic hepatitis B (CHB). The regimen involves the addition of **peginterferon alfa-2a** (typically at a 180 µg weekly dose) to patients who are already receiving long-term nucleos(t)ide analogue (NA) therapy, such as **entecavir** or **tenofovir disoproxil fumarate**. The primary objective of this strategy is to induce higher rates of HBsAg loss, often referred to as a 'functional cure,' by combining the direct antiviral suppression of NAs with the immunomodulatory and broader antiviral effects of pegylated interferon. This approach targets patients who have already achieved viral suppression on NAs but remain HBsAg positive.

Brand names

PegasysBaracludeViread

Other names

pegylated interferon-Tongji Hospital-chronic hepatitis BCOST study regimenSequential PegIFN therapy